Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Supportive Cancer Care

    US SUPPORTIVE CANCER CARE PARTNER

    An Introduction to Supportive Cancer Care

    Supportive care is an important area within cancer, aiming to improve the quality of life of patients by treating or preventing symptoms and side effects caused by treatment, whilst providing psychological and social support. Along with advancing treatments to address side effects such as nausea and vomiting, research into complementary and alternative therapies such as yoga and mindfulness is in progress.

    Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Supportive Cancer Care Content

    Supportive Cancer Care
    Top 3 highlights from EONS16: Virpi Sulosaari

    This year, in partnership with ESMO23, the European Oncology Nurses Society (EONS) held its annual meeting – EONS16. The theme of EONS16 was ‘Cancer nursing: Building on innovation and building back better’. To address this, the event covered a wide range of topics including health promotion, prevention and screening; supportive and person-centred care; symptom management; […]

    Supportive Cancer Care
    Developed by Touch
    Johan de Munter: Reflections as President of EONS, hopes for 2024 and European Cancer Nursing Day 2023
    Watch Time: 5 mins

    President of the European Oncology Nursing Society (EONS), Johan de Munter, reflects on his tenure as President, steering the society through the COVID-19 pandemic, his hopes for the society over the next 12 months, including a snapshot into what we can look forward to at the EONS16 annual meeting. Finally, he discusses the these of […]

    Supportive Cancer Care
    Trilaciclib: A First-in-class Therapy to Reduce Chemotherapy-induced Myelosuppression
    Joanna A Young, Antoinette R Tan

    touchREVIEWS in Oncology & Haematology. 2022;18(2):152-8 DOI: https://doi.org/10.17925/OHR.2022.18.2.152

    Chemotherapy-induced myelosuppression has long been considered a toxicity that limits the dose of cytotoxic agents, which contributes to significant morbidity and mortality.1 Sub-optimal dose intensity may decrease the efficacy of therapy, thereby compromising progression-free survival (PFS) and overall survival (OS) benefits.2 Chemotherapy-induced myelosuppression is often managed with granulocyte-colony stimulating factors (G-CSFs) and erythropoiesis-stimulating agents (ESAs) […]

    Supportive Cancer Care
    Foreword – touchREVIEWS in Oncology & Haematology – VOLUME 18 ISSUE 1 – 2022

    Welcome to the latest edition of touchREVIEWS in Oncology & Haematology. Despite the success of the human papillomavirus vaccination programme, cervical cancer remains one of the most common cancers in women, and advanced disease carries a poor prognosis. Lebreton et al. review data from the KEYNOTE-826 Phase III trial, which showed the benefits of adding pembrolizumab […]

    Supportive Cancer Care
    Watch Time: 35 mins
    touchEXPERT OPINIONS
    Appropriate use of opioids to address cancer-related pain
    Prof. Sebastiano Mercadante, Prof. Marie Fallon, Prof. Frank Elsner Translations available:

    Three pain specialists consider the use of opioids for the management of cancer-related pain.

    Learning objectives
    Learning Objectives
    • Appraise current best practice for the management of cancer-related pain
    • Apply active management of the side effects of opioids in patients with cancer-related pain
    • Discuss how to prevent potential risks and abuse of opioids in patients with cancer-related pain
    Leukaemia, Haematological Malignancies, Haematology, Supportive Cancer Care
    Watch Time: 46 mins
    touchMDT
    Multidisciplinary management of chronic myeloid leukaemia in the later-line setting: A holistic approach
    Prof. Dr. Andreas Hochhaus, Dr Kim Bee Tan, Mr Johan De Munter, Ms Jelena Čugurović

    Watch chronic myeloid leukaemia (CML) specialists within a multidisciplinary team, plus a CML patient advocate, discuss the later-line management of CML.

    Learning objectives
    Learning Objectives
    • Discuss the later-line treatment of chronic myeloid leukaemia, including T315I mutation-positive disease
    • Manage the toxicities associated with tyrosine kinase inhibitor treatments for chronic myeloid leukaemia
    • Recognize the impact of tyrosine kinase inhibitors on quality of life for patients with chronic myeloid leukaemia
    Supportive Cancer Care
    Foreword – touchREVIEWS in Oncology & Haematology – VOLUME 17 ISSUE 2 – 2021
    Shaji K Kumar

    touchREVIEWS in Oncology & Haematology - 2021;17(2):55

    Welcome to the winter edition of touchREVIEWS in Oncology & Haematology. Despite the continued impact of the COVID-19 pandemic on cancer care, 2021 has seen important advances in many areas of oncology, which is reflected in our diverse range of articles. We begin with one of our popular expert interviews, in which Axel Merseburger discusses the […]

    Supportive Cancer Care
    Foreword – touchREVIEWS in Oncology & Haematology – VOLUME 17 ISSUE 1 – 2021
    Shaji K Kumar, Axel Merseburger

    touchREVIEWS in Oncology & Haematology. 2021;17(1):1-2

    Welcome to the inaugral issue of touchREVIEWS in Oncology & Haematology (formerly Oncology & Hematology Review [US]), which aims to summarize the latest clinical data and provide practical advice to help busy physicians in their daily practice. As co-editors-in-chief of this new title, we are excited to bring you a range of interesting and informative […]

    Supportive Cancer Care
    Professor D’Ugo: Don’t Miss Out on Registering for the ESSO 40!

    Professor Domenico D’Ugo, President of the European Society of Surgical Oncology (ESSO), shares what we can look forward to at the annual meeting in November!

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup